StockStory Flags Vertex as a Nasdaq 100 Stock to Watch, Questions Workday and Mondelez

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory highlights Vertex Pharmaceuticals as a Nasdaq 100 stock with huge potential while expressing caution on Workday and Mondelez. Vertex, with a market cap of $121.1 billion, posted 13.8% annual revenue growth over five years and a strong free cash flow margin of 24.7%. Workday, valued at $35.03 billion, faces slowing demand with estimated sales growth of 10.9% and trades at 3.3x forward price-to-sales. Mondelez, at a $75.38 billion market cap, saw earnings per share fall 2% annually over three years and has an estimated sales growth of just 2.4%, trading at 18.4x forward P/E.

Impact on stocks 4

Cloud & Digital Infrastructure▼ · 2 stocks
Workday Inc
WDAY
▼ NegativeDemandrelevance

Article questions Workday due to slowing demand with estimated sales growth of 10.9% and high valuation.

Consumer Staples▼ · 1 stocks
Mondelez International Inc
MDLZ
▼ NegativeDemandrelevance

Article questions Mondelez due to slowing demand with estimated sales growth of only 2.4% and falling EPS.

Biotech & Genomic Medicine▲ · 1 stocks
Vertex Pharmaceuticals Inc
VRTX
▲ PositiveCapitalrelevance

Article highlights Vertex's strong financials: 13.8% annual revenue growth and 24.7% free cash flow margin.

© 2026 MarketDXNews